These changes were also related to the high production of intracellular glucagon-like peptide-2 (GLP-2), the intestinotrophic pro-glucagon-derived peptide associated with gut permeability, thus decreasing obesity-related gastric inflammatory and cardiovascular disorders. The gene discussed is GCG; the disease is cardiovascular disorder.